[1] de Franchis R, Bosch J, Garcia-Tsao G, et al. Baveno VII-Renewing consensus in portal hypertension. J Hepatol, 2022, 76(4):959-974.
[2] De Gottardi A, Sempoux C, Berzigotti A. Porto-sinusoidal vascular disorder. J Hepatol, 2022, 77(4):1124-1135.
[3] De Gottardi A, Rautou PE, Schouten J, et al. Porto-sinusoidal vascular disease: proposal and description of a novel entity. Lancet Gastroenterol Hepatol, 2019, 4(5):399-411.
[4] Toksvang LN, Schmidt MS, Arup S, et al. Hepatotoxicity during 6-thioguanine treatment in inflammatory bowel disease and childhood acute lymphoblastic leukaemia: A systematic review. PLoS One, 2019, 14(5): e 0212157.
[5] Cotte L, Bénet T, Billioud C, et al. The role of nucleoside and nucleotide analogues in nodular regenerative hyperplasia in HIV-infected patients: a case control study. J Hepatol, 2011, 54(3):489-496.
[6] Murai Y, Ohfuji S, Fukushima W, et al. Prognostic factors in patients with idiopathic portal hypertension: Two Japanese nationwide epidemiological surveys in 1999 and 2005. Hepatol Res, 2012, 42(12):1211-1220.
[7] Harmanci O, Bayraktar Y. Clinical characteristics of idiopathic portal hypertension. World J Gastroenterol, 2007, 13(13):1906-1911.
[8] Besmond C, Valla D, Hubert L, et al. Mutations in the novel gene FOPV are associated with familial autosomal dominant and non-familial obliterative portal venopathy. Liver Int, 2018, 38(2):358-364.
[9] Barge S, Grando V, Nault JC, et al. Prevalence and clinical significance of nodular regenerative hyperplasia in liver biopsies. Liver Int, 2016, 36(7):1059-1066.
[10] Siramolpiwat S, Seijo S, Miquel R, et al. Idiopathic portal hypertension: natural history and long-term outcome. Hepatology, 2014, 59(6):2276-2285.
[11] Pugliese N, di Tommaso L, Lleo A, et al. High prevalence of porto-sinusoidal vascular disease in patients with constantly elevated gamma-glutamyl transferase levels. Liver Int, 2022, 42(7):1692-1695.
[12] Cazals-Hatem D, Hillaire S, Rudler M, et al. Obliterative portal venopathy: portal hypertension is not always present at diagnosis.?J Hepatol, 2011, 54(3):455-461.
[13] W?ran K, Semmler G, Jachs M, et al. Clinical Course of Porto-Sinusoidal Vascular Disease Is Distinct From Idiopathic Noncirrhotic Portal Hypertension. Clin Gastroenterol Hepatol, 2022, 20(2):e251-e266.
[14] Cerda Reyes E, González-Navarro EA, Magaz M, et al. Autoimmune biomarkers in porto-sinusoidal vascular disease: Potential role in its diagnosis and pathophysiology. Liver Int, 2021, 41(9):2171-2178.
[15] Mackie I, Eapen CE, Neil D, et al. Idiopathic noncirrhotic intrahepatic portal hypertension is associated with sustained ADAMTS13 Deficiency. Dig Dis Sci, 2011, 56(8):2456-2465.
[16] Kang JH, Kim DH, Kim SY, et al. Porto-sinusoidal vascular disease with portal hypertension versus liver cirrhosis: differences in imaging features on CT and hepatobiliary contrast-enhanced MRI. Abdom Radiol (NY), 2021, 46(5):1891-1903.
[17] Lampichler K, Semmler G, W?ran K, et al. Imaging features facilitate diagnosis of porto-sinusoidal vascular disorder [published online ahead of print, 2022 Sep 27]. Eur Radiol, 2022, 10.1007/s00330-022-09132-4.
[18] Okuda K, Nakashima T, Kojiro M, et al. Hepatocellular carcinoma without cirrhosis in Japanese patients. Gastroenterology, 1989, 97(1):140-146.
[19] Maruyama H, Okugawa H, Kobayashi S, et al. Non-invasive portography: a microbubble-induced three-dimensional sonogram for discriminating idiopathic portal hypertension from cirrhosis. Br J Radiol, 2012, 85(1013):587-595.
[20] Elkrief L, Lazareth M, Chevret S, et al. Liver Stiffness by Transient Elastography to Detect Porto-Sinusoidal Vascular Liver Disease With Portal Hypertension. Hepatology, 2021, 74(1):364-378.
[21] Ahmad AK, Atzori S, Taylor-Robinson SD, et al. Spleen stiffness measurements using point shear wave elastography detects noncirrhotic portal hypertension in human immunodeficiency virus. Medicine (Baltimore), 2019, 98(47): e17961. |
